Business
Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors
Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors\nLeveraging the R&D platform to broaden pipeline of offerings\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors.\n\n \n \n\n \nDr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company's clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE). \nThe patent protection of new disease specific and patient specific cannabinoid compositions and treatment protocols has already begun, with these four patent applications filed this month alone, with several and more in progress.  \nDr. Eyal Ballan, CTO and Co-Founder, said: \"Cannabics is broadening its potential offerings to the healthcare industry. We believe that the company's expertise in clinical evaluation of cannabinoid formulations has now been brought to bear in designing specific drugs and treatments which will potentially benefit many patients globally.\"\nAbout Cannabics PharmaceuticalsCannabics Pharmaceuticals Inc. (CNBX) is a U.S-based public company that is developing a platform which leverages novel drug-sc...